Chris Jacobs bought Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)
Chris Jacobs (R-NY), a U.S. Representative, has disclosed 1 trade in Amylyx Pharmaceuticals Inc (AMLX) since 2022, a single purchase, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a purchase: Chris Jacobs bought $1,001 - $15,000 of Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) on October 12, 2022. Since that trade, AMLX is down -41.30% against the S&P 500 up +114.39%, an outperformance of -155.69%.
Data updated
Chris Jacobs's AMLX trades vs the price
AMLX is down -41.30% since Chris Jacobs bought on October 12, 2022, versus +114.39% for the S&P 500.
Performance since this trade
All Chris Jacobs AMLX trades
Chris Jacobs & AMLX trading FAQ
Is it legal for Chris Jacobs to trade Amylyx Pharmaceuticals Inc (AMLX) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Amylyx Pharmaceuticals Inc (AMLX), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Chris Jacobs buy AMLX?
Chris Jacobs disclosed a purchase of $1,001 - $15,000 of Amylyx Pharmaceuticals Inc (AMLX) on October 12, 2022, according to public STOCK Act filings.
How has AMLX performed since Chris Jacobs's trade?
Since Chris Jacobs bought AMLX on October 12, 2022, the stock is down -41.30%, versus +114.39% for the S&P 500 over the same period, an outperformance of -155.69%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional AMLX trades?
Quantellect tracks every disclosed congressional trade in Amylyx Pharmaceuticals Inc (AMLX) on the Amylyx Pharmaceuticals Inc congressional trading page, which aggregates filings across all members of Congress.
Chris Jacobs's AMLX tradesAll congressional filings for Amylyx Pharmaceuticals IncChris Jacobs's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.